scholarly journals May Measurement Month 2017: an analysis of blood pressure screening results from the United Arab Emirates—Northern Africa and Middle East

2019 ◽  
Vol 21 (Supplement_D) ◽  
pp. D118-D120 ◽  
Author(s):  
Afzalhussein Yusufali ◽  
Nooshin Bazargani ◽  
Amrish Agrawal ◽  
Khalifa Muhammed ◽  
Hanan Obaid ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Middle East ◽  
United Arab Emirates ◽  
Northern Africa ◽  
Blood Pressure Screening

scholarly journals May Measurement Month 2017: an analysis of blood pressure screening in Sudan—Northern Africa and Middle East

2019 ◽  
Vol 21 (Supplement_D) ◽  
pp. D111-D114 ◽  
Author(s):  
Ibtisam Ali ◽  
Hind Behairy ◽  
Ashraf Abugroun ◽  
Thomas Beaney ◽  
Elsa Kobeissi ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Middle East ◽  
Northern Africa ◽  
Blood Pressure Screening

scholarly journals Blood Pressure Screening in the Workplace

AAOHN Journal ◽  
1989 ◽  
Vol 37 (1) ◽  
pp. 14-17 ◽  
Author(s):  
Betsy Leigh ◽  
Diane Guisinger ◽  
Judy Fech
Keyword(s):  
Blood Pressure ◽  
Blood Pressure Screening

scholarly journals 1293. Sulbactam-durlobactam is active against recent, multi-drug resistant Acinetobacter baumannii clinical isolates from the Middle East

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S662-S662
Author(s):  
Alita Miller ◽  
Sarah McLeod ◽  
Samir Moussa ◽  
Meredith Hackel
Keyword(s):  
Antibacterial Activity ◽  
Middle East ◽  
Acinetobacter Baumannii ◽  
United Arab Emirates ◽  
Blood Stream ◽  
Multidrug Resistant ◽  
Clinical Isolates ◽  
Surveillance Systems ◽  
Spectrum Activity

Abstract Background The incidence of infections caused by multidrug-resistant (MDR) Acinetobacter baumannii (Ab) is increasing at an alarming rate in certain regions of the world, including the Middle East. Sulbactam (SUL) has intrinsic antibacterial activity against Ab; however, the prevalence of β-lactamases in Ab has limited its therapeutic utility. Durlobactam (DUR, formerly ETX2514) is a diazabicyclooctenone β-lactamase inhibitor with broad-spectrum activity against Ambler class A, C and D β-lactamases that restores SUL activity in vitro against MDR Ab. SUL-DUR is an antibiotic designed to treat serious infections caused by Acinetobacter, including multidrug-resistant strains, that is currently in Phase 3 clinical development. In global surveillance studies of >3600 isolates from 2012-2017, the MIC90 of SUL-DUR was 2 mg/L. Although surveillance systems to monitor MDR infections in the Middle East are currently being established, quantitative, prevalence-based data are not yet available. Therefore, the potency of SUL-DUR was determined against 190 recent, diverse Ab clinical isolates from this region. Methods 190 Ab isolates were collected between 2016 - 2018 from medical centers located in Israel (N = 47), Jordan (N = 36), Qatar (N = 13), Kuwait (N = 42), Lebanon (N = 8), Saudi Arabia (N = 24) and United Arab Emirates (N = 20). Seventy-five percent and 20.5% of these isolates were from respiratory and blood stream infections, respectively. Susceptibility to SUL-DUR and comparator agents was performed according to CLSI guidelines, and data analysis was performed using CLSI and EUCAST breakpoint criteria where available. Results This collection of isolates was 86% carbapenem-resistant and 90% sulbactam-resistant (based on a breakpoint of 4 mg/L). The addition of SUL-DUR (fixed at 4 mg/L) decreased the sulbactam MIC90 from 64 mg/L to 4 mg/L. Only 3 isolates (1.6%) had SUL-DUR MIC values of > 4 mg/L. This potency was consistent across countries, sources of infection and subsets of resistance phenotypes. Conclusion SUL-DUR demonstrated potent antibacterial activity against recent clinical isolates of Ab from the Middle East, including MDR isolates. These data support the global development of SUL-DUR for the treatment of MDR Ab infections. Disclosures Alita Miller, PhD, Entasis Therapeutics (Employee) Sarah McLeod, PhD, Entasis Therapeutics (Employee) Samir Moussa, PhD, Entasis Therapeutics (Employee)

scholarly journals Limited Genetic Diversity Detected in Middle East Respiratory Syndrome-Related Coronavirus Variants Circulating in Dromedary Camels in Jordan

Viruses ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 592
Author(s):  
Stephanie N. Seifert ◽  
Jonathan E. Schulz ◽  
Stacy Ricklefs ◽  
Michael Letko ◽  
Elangeni Yabba ◽  
...  
Keyword(s):  
Genetic Diversity ◽  
Middle East ◽  
United Arab Emirates ◽  
Sequence Data ◽  
Case Fatality ◽  
High Sensitivity ◽  
Middle East Respiratory Syndrome ◽  
Full Genome Sequence ◽  
Genome Sequences ◽  
Dromedary Camels

Middle East respiratory syndrome-related coronavirus (MERS-CoV) is a persistent zoonotic pathogen with frequent spillover from dromedary camels to humans in the Arabian Peninsula, resulting in limited outbreaks of MERS with a high case-fatality rate. Full genome sequence data from camel-derived MERS-CoV variants show diverse lineages circulating in domestic camels with frequent recombination. More than 90% of the available full MERS-CoV genome sequences derived from camels are from just two countries, the Kingdom of Saudi Arabia (KSA) and United Arab Emirates (UAE). In this study, we employ a novel method to amplify and sequence the partial MERS-CoV genome with high sensitivity from nasal swabs of infected camels. We recovered more than 99% of the MERS-CoV genome from field-collected samples with greater than 500 TCID50 equivalent per nasal swab from camel herds sampled in Jordan in May 2016. Our subsequent analyses of 14 camel-derived MERS-CoV genomes show a striking lack of genetic diversity circulating in Jordan camels relative to MERS-CoV genome sequences derived from large camel markets in KSA and UAE. The low genetic diversity detected in Jordan camels during our study is consistent with a lack of endemic circulation in these camel herds and reflective of data from MERS outbreaks in humans dominated by nosocomial transmission following a single introduction as reported during the 2015 MERS outbreak in South Korea. Our data suggest transmission of MERS-CoV among two camel herds in Jordan in 2016 following a single introduction event.

Events in Northern Africa and Middle East: Causes and Consequences

2011 ◽  
pp. 11-25
Author(s):  
I. Labinskaya
Keyword(s):  
Middle East ◽  
North Africa ◽  
Large Scale ◽  
Arab Countries ◽  
Northern Africa ◽  
External Factors ◽  
Wide Range ◽  
The Usa ◽  
Oriental Studies

Political developments in North Africa and the Middle East that have begun in January 2011 are gaining strength and involve an increasing number of Arab countries. The participants of the Roundtable – experts from IMEMO, Institute of Oriental Studies (RAS), Institute of the USA and Canada (RAS) and Mrs. E. Suponina from “Moscow News” newspaper analyzed a wide range of issues associated with these events. Among them are: 1) the reasons for such a large-scale explosion, 2) the nature of the discussed developments (revolutions, riots?) and who are the subjects of the current “Arab drama”, 3) the role of Islam and political Islamism, 4) the role of external factors.

Events in Northern Africa and Middle East: Causes and Consequences (the end)

2011 ◽  
pp. 52-66
Author(s):  
I. Labinskaya
Keyword(s):  
Middle East ◽  
North Africa ◽  
Northern Africa ◽  
External Factors ◽  
Protest Movements ◽  
Research Institutes ◽  
Internal And External Factors

A discussion of the developments in North Africa and Middle East by a group of experts from three research institutes and the newspaper “Moscow news” is continued. It has begun in the previous of the magazine. Now, an attempt is made to identify possible scenarios of further developments, as well as the roles of the various actors, including protest movements. Internal and external factors of what is happening in these regions are classified.

Sign in / Sign up

Export Citation Format

Share Document